WallStSmart

Alumis Inc (ALMS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Alumis Inc stock (ALMS) is currently trading at $23.07. Alumis Inc PS ratio (Price-to-Sales) is 131.88. Analyst consensus price target for ALMS is $39.40. WallStSmart rates ALMS as Sell.

  • ALMS PE ratio analysis and historical PE chart
  • ALMS PS ratio (Price-to-Sales) history and trend
  • ALMS intrinsic value — DCF, Graham Number, EPV models
  • ALMS stock price prediction 2025 2026 2027 2028 2029 2030
  • ALMS fair value vs current price
  • ALMS insider transactions and insider buying
  • Is ALMS undervalued or overvalued?
  • Alumis Inc financial analysis — revenue, earnings, cash flow
  • ALMS Piotroski F-Score and Altman Z-Score
  • ALMS analyst price target and Smart Rating
ALMS

Alumis Inc

NASDAQHEALTHCARE
$23.07
$0.29 (-1.24%)
52W$2.76
$30.60
Target$39.40+70.8%

📊 No data available

Try selecting a different time range

WallStSmart

Smart Analysis

Alumis Inc (ALMS) · 6 metrics scored

Smart Score

18
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.

Alumis Inc (ALMS) Key Strengths (2)

Avg Score: 8.5/10
Institutional Own.Quality
71.75%10/10

71.75% of shares held by major funds and institutions

Market CapQuality
$3.17B7/10

Mid-cap company balancing growth potential with stability

Supporting Valuation Data

ALMS Target Price
$39.4
50% Upside

Alumis Inc (ALMS) Areas to Watch (4)

Avg Score: 1.0/10
Return on EquityProfitability
-86.70%0/10

Company is destroying shareholder value

Operating MarginProfitability
-5067.00%0/10

Losing money on operations

Price/SalesValuation
131.882/10

Very expensive at 131.9x annual revenue

Price/BookValuation
8.122/10

Very expensive at 8.1x book value

Supporting Valuation Data

Price/Sales (TTM)
131.88
Overvalued
EV/Revenue
125.89
Overvalued

Alumis Inc (ALMS) Detailed Analysis Report

Overall Assessment

This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.5/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Institutional Own., Market Cap.

The Bear Case

The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (131.88), Price/Book (8.12) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -86.70%, Operating Margin at -5067.00%.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -86.70% needing improvement to support the investment thesis. Third, top-line growth trajectory.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

ALMS Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

ALMS's Price-to-Sales ratio of 131.88x sits near its historical average of 149.01x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 21% below its historical high of 167.52x set in Mar 2026, and 0% above its historical low of 131.88x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~167.5x as trailing revenue scaled faster than the stock price.

Compare ALMS with Competitors

Top BIOTECHNOLOGY stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Alumis Inc (ALMS) · HEALTHCAREBIOTECHNOLOGY

The Big Picture

Alumis Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 24M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.

Key Findings

Low Leverage

Debt-to-equity ratio of 0.10 indicates a conservative balance sheet with 65M in cash.

Heavy R&D Investment

Spending 318% of revenue (77M) on R&D, reinforcing its commitment to innovation and future growth.

Negative Free Cash Flow

Free cash flow is -72M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.

What to Watch Next

Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alumis Inc.

Bottom Line

Alumis Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions

Total Buys
0
Total Sells
0

Data sourced from SEC Form 4 filings

Last updated: 8:21:40 AM

About Alumis Inc(ALMS)

Exchange

NASDAQ

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Country

USA

Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.

Visit Alumis Inc (ALMS) Website
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080